Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1CNS 1Breast 1

Conditions

Kidney Neoplasms 1Castrate-resistant Prostate Cancer 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × dactolisib × Genitourinary × Clear all
NCT01717898 2018-03-27

A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer

University of California, San Francisco

Phase 1/2 Terminated
6 enrolled 5 charts
Genitourinary

Castrate-resistant Prostate Cancer

NCT01453595 2016-02-29

BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Terminated
10 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡